clinical trial · NCT05028582
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
Scalp PsoriasisRoflumilast Foam 0.3%Vehicle Foam
brief summary
This was a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-154) 0.3% foam vs vehicle foam applied once daily (qd) for 8 weeks by participants with plaque psoriasis of the scalp and body.
started
Aug 24, 2021
primary completion
Jun 3, 2022
completion
Jun 3, 2022
last updated
Jul 17, 2025
official title
A Randomized tRial Employing topiCal roflumilasT Foam to Treat Scalp Psoriasis (ARRECTOR)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol